2 results
Approved WMORecruiting
The primary objective of this study is to compare in a non-inferiority design the safety and efficacy of iwFR (or comparable resting diastolic indices)-guided complete revascularization after (within 1-45 days) with iwFR (or comparable resting…
Approved WMORecruiting
Primary:To determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-5890 when used as monotherapy and in combination with pembrolizumab in the dose escalation and confirmation phase and the dose…